Can’t Stop, Won’t Stop the Search for Relief: Scratching the Surface of Itch and Inflammation in Moderate-to-Severe AD



Release date: November 11, 2020
Expiration date: November 11, 2021
Estimated time to complete activity: 1.25 hour(s)



Michael S. Blaiss, MD, FACAAI
Clinical Professor of Pediatrics
Medical College of Georgia
Augusta University
Augusta, Georgia


Jonathan I. Silverberg, MD, PhD, MPH
Associate Professor of Dermatology
Director, Clinical Research & Contact Dermatitis
School of Medicine and Health Sciences
The George Washington University
Washington, District of Columbia


James L. Sublett, MD
Co-Founder & Chief Medical Officer
Family Allergy & Asthma
Louisville, Kentucky


Although moderate-to-severe atopic dermatitis (AD) manifests on the skin’s surface, it’s far from superficial; it is a disease that originates from the deepest interior of the immune system to profoundly destabilize all psychophysical aspects of health-related quality of life. As the pathophysiology of AD has begun to unravel, it is becoming clear that to be effective, treatment needs to target the proinflammatory pathways and cytokines that are the pruritogenic core of this disease.

This video-based activity will help translate the impact of comorbid conditions and burden of itch in moderate-to-severe AD to improve treatment selection, increase familiarity with clinical trial data regarding emerging targeted treatments for moderate-to-severe AD, and interpret endpoints results from recent head-to-head studies.


This program is intended for allergists, immunologists, dermatologists, specialty advanced practice providers, and other healthcare professionals involved in the management and treatment of patients with moderate-to-severe AD.


Upon completion of this educational activity, participants should be able to:

  • Apply knowledge gained about comorbidities and itch associated with moderate-to-severe AD in order to personalize treatment selection
  • Review clinical trials outcomes and current statuses of emerging targeted therapies for moderate-to-severe AD
  • Interpret endpoint results from phase 3 clinical trials comparing the biologic dupilumab with Janus kinase inhibitors

There are no fees for participating and receiving CME credit for this activity. During the period of November 11, 2020 through November 11, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.




Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Michael S. Blaiss, MD, FACAAI
Consulting Fees:
Sanofi Regeneron

Jonathan I. Silverberg, MD, PhD, MPH
Consulting Fees:
AbbVie, Arena, Asana, Bluefin, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly, Kiniksa, Leo, Luna, Medimmune, Menlo, Novartis, Pfizer Inc., Regeneron, Sanofi Genzyme
Speakers’ Bureaus: Regeneron, Sanofi Genzyme
Contracted Research: Galderma, GlaxoSmithKline

James L. Sublett, MD does not have any conflicts of interest to disclose.

The Integrity Continuing Education, Inc. planners/managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended.

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
Click here for more information on minimum system requirements.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


Provided by Integrity Continuing Education, Inc.


Supported by an educational grant from Pfizer, Inc.

Continue to Pretest